Learn the key warning signs of prostate cancer that men often overlook. Early awareness can make all the difference.

An experimental immunotherapy drug called VIR-5500 has driven prostate-specific antigen (PSA) levels down by as much as 99% in some men with metastatic castration-resistant prostate cancer, according ...

What did the study reveal about testosterone levels and cancer progression? Researchers found that prostate cancer patients with low baseline testosterone levels (300 ng/dl and lower) had a ...

Prostate cancer is the most common cancer in men throughout the United States. Most men do not realize they have cancer due ...

A new study led by researchers at The University of Texas MD Anderson Cancer Center found that prostate cancer patients with low testosterone levels may have a higher risk of cancer progressing to a ...

A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel ...

Dr. Donald Trump answers the question: 'Prognosis For Prostate Cancer Recovery?' March 16, 2009 -- Question: What is the prognosis for recovery from prostate cancer? Answer: I think it's a key point ...

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients.

CURE highlights prostate cancer advancements from Day One of the 2026 ASCO Genitourinary Cancers Symposium.

Staging means finding out how far prostate cancer has spread in your body. Physicians group prostate cancers into stages I (1) through IV (4), with stage I being the least advanced and stage IV being ...

Overview of Ac‑225 PSMA therapy, what real patient cases can illustrate about the treatment pathway, and key steps for eligibility review and choosing a center.

There are different ways to manage fatigue during prostate cancer treatment, including exercise, sleep, complementary ...